



Ref: FOIA Reference 2024/25-023

Date: 23<sup>rd</sup> April 2024

Email [foi@uhnm.nhs.uk](mailto:foi@uhnm.nhs.uk)

Dear

I am writing to acknowledge receipt of your email dated 11th March 2024 requesting information under the Freedom of Information Act (2000) regarding Urothelial and Endometrial Cancer

On 9<sup>th</sup> April 2024 you sent in another request, we responded with the following:

UHNM has received several requests that are asking for similar information that are from the same person/company, therefore we are contacting you to inform you that under section 12 of the FOI Act we were aggregating these requests on Urothelial and Endometrial Cancer and Haemophilia A.

Your new reference number for **both is 023-2425**

The section 12 exemption states:

The authority can combine related requests received within a period of 60 consecutive days from:

- The same person or
- People who appear to be acting in concert or in pursuance of a campaign.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

### **Request #1**

**Q1 I am researching the incidence and treatment of Urothelial and Endometrial Cancer. I would greatly appreciate if you could answer the following questions.**

**How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:**

- **Atezolizumab (Tecentriq)**
- **Avelumab (Bavencio)**
- **Carboplatin single agent or in any other combination**
- **Carboplatin with Gemcitabine**
- **Carboplatin with Paclitaxel**
- **Cisplatin single agent or in any other combination**

- **Cisplatin with Gemcitabine**
- **Nivolumab (Opdivo)**
- **Pembrolizumab (Keytruda)**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information.* However as the Trust is committed to openness and transparency we can band the numbers as being <5  
*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- Atezolizumab (Tecentriq) - <5
- Avelumab (Bavencio) - <5
- Carboplatin single agent or in any other combination - 0
- Carboplatin with Gemcitabine - 5
- Carboplatin with Paclitaxel - 0
- Cisplatin single agent or in any other combination - 0
- Cisplatin with Gemcitabine - 8
- Nivolumab (Opdivo) - 0
- Pembrolizumab (Keytruda) - 0
- Other active systemic anti-cancer therapy - <5
- Palliative care only - data not held for patients on Best Supportive Care, as not on active SACT (Systemic Anti-Cancer Therapy)

**Q2 Does your Trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other Trust do you refer endometrial cancer patients to for SACT treatments?**

A2 Yes

**Q3 How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:**

- **Dostarlimab (Jemperli)**
- **Hormone therapy (Progesterone or Letrozole)**
- **Pembrolizumab (Keytruda) monotherapy**
- **Pembrolizumab + Lenvatinib (Keytruda + Lenvima)**
- **Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)**
- **Any other SACT**

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information.* However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- Dostarlimab (Jemperli) - <5
- Hormone therapy (Progesterone or Letrozole) – Unable to answer – Mainly provided by Primary Care
- Pembrolizumab (Keytruda) monotherapy - 0
- Pembrolizumab + Lenvatinib (Keytruda + Lenvima) - 0
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) - 15
- Any other SACT - <5

**Q4 In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?**

A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information.* However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

## Request #2

**Q1 I am researching the incidence and treatment of Haemophilia A across the UK. I would greatly appreciate if you could answer to the following questions.**

**How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information.* However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed. See below:*

82 registered  
<5 moderate  
<5 severe  
78 mild

**Q2 In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?**

- Advate
- Adynovi

- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Nuwiq
- Obizur
- Refacto AF
- Any other products

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information.* However as the Trust is committed to openness and transparency we can band the numbers as being <5  
*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- Advate == <5
- Adynovi =0
- Elocta= <5
- Esperoct=0
- Factor Eight Inhibitor Bypass Activity (FEIBA) =<5
- Hemlibra (standalone)=<5
- Hemlibra in combination with any Factor VIII=0
- NovoEight=0
- NovoSeven RT=0
- Nuwiq=0
- Obizur =0
- Refacto AF=0
- Any other products =0

**Q3 For patients treated with Advate in the last three months, please provide:**

- **the number of haemophilia A patients treated prophylactically**
- **the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)**

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information.* However as the Trust is committed to openness and transparency we can band the numbers as being <5  
*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- the number of haemophilia A patients treated prophylactically=<5

- the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)=0

**Q4 In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?**

- **Advate**
- **Adynovi**
- **Elocta**
- **Esperoct**
- **Factor Eight Inhibitor Bypass Activity (FEIBA)**
- **Hemlibra (standalone)**
- **Hemlibra in combination with any Factor VIII**
- **NovoEight**
- **NovoSeven RT**
- **Nuwiq**
- **Obizur**
- **Refacto AF**
- **Any other products**

A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. Personal information. However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- Advate =<5
- Adynovi =0
- Elocta =<5
- Esperoct =0
- Factor Eight Inhibitor Bypass Activity (FEIBA) =0
- Hemlibra (standalone)=<5
- Hemlibra in combination with any Factor VIII=0
- NovoEight =0
- NovoSeven RT =0
- Nuwiq=0
- Obizur =0
- Refacto AF=0
- Any other products=0

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

Yours,



**Rachel Montinaro**  
Data Security and Protection Manager - Records